Abstract: Pancreatic cancer organoids prepared by a method of the present invention sufficiently reflect the interaction between cancer cells and endothelial cells, that is, cross-talk with the vascular niche, and thus they can show the characteristics of cancer-initiating cells (CICs) present in the organism environment, compared to conventional cancer organoids. Accordingly, the clinical applicability and reliability of the screened drug may be further remarkably increased.

Abstract: Provided are a composition including a Kang AI 1 (KAI1) polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.

Abstract: A method for controlling braking force in a regenerative brake cooperation control system can maximally use regenerative braking force of a rear wheel simultaneously while improving vehicular braking stability by preventing the rear wheel from being locked earlier than a front wheel. The method includes controlling braking forces of the front wheel and the rear wheel by considering a distribution of total vehicular braking force including a coasting regenerative braking force in the regenerative brake cooperation control system in an eco-friendly vehicle which can perform regenerative braking in the rear wheel or both the front wheel and the rear wheel.

Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.

Abstract: Provided is a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1h, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.

Abstract: Provided is a KAI1 protein controlling the cell cycle of a hematopoietic stem cell and a use thereof, and more specifically, a composition including a KAI1(CD82) polypeptide or a gene encoding the same for controlling the cell cycle of a hematopoietic stem cell, or a pharmaceutical composition for preventing or treating blood tumors. Further provided, KAI1(CD82) is expressed only in a hematopoietic stem cell (LT-HSC) which is the uppermost stem cell in the hierarchy of the hematopoietic stem cell, can obtain an LT-HSC with high purity using the KAI1, and thus can inhibit various side effects of hematopoietic stem cell transplantation by transplanting only an LT-HSC with high purity. In addition, KAI1 importantly acts on the quiescence of an LT-HSC, and has resistance against cell damage due to various stresses (5-FU, irradiation, etc.) by maintaining the quiescence of the LT-HSC.

Abstract: A method for controlling braking force in a regenerative brake cooperation control system can maximally use regenerative braking force of a rear wheel simultaneously while improving vehicular braking stability by preventing the rear wheel from being locked earlier than a front wheel. The method includes controlling braking forces of the front wheel and the rear wheel by considering a distribution of total vehicular braking force including a coasting regenerative braking force in the regenerative brake cooperation control system in an eco-friendly vehicle which can perform regenerative braking in the rear wheel or both the front wheel and the rear wheel.

Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.

Abstract: A pushing force controlling apparatus for a pedal simulator that includes a simulator cylinder in which a first pipe and a second pipe extending from a master cylinder are connected to a front side and a rear side thereof, respectively. A first solenoid valve and a second solenoid valve are installed in the first pipe and the second pipe, respectively and a first piston and a second piston are disposed at a front side and a rear side of an interior of the simulator cylinder. A buffering member is installed between the first piston and the second piston, and pedal pushing force characteristics are controlled by variably setting a position of the second piston in the simulator cylinder using an amount of fluid provided from the master cylinder during an operation of a pedal.

Abstract: There are provided a pharmaceutical composition for treating immune-related diseases, a pharmaceutical composition for treating ischemic diseases, a pharmaceutical composition for promoting lymphangiogenesis, a pharmaceutical composition for treating neurological diseases, a pharmaceutical composition for treating metabolic diseases, and the like, which contain blood-born hematospheres, and more specifically, may differentiate into inflammatory mononuclear cells, vascular endothelial cells, vascular smooth muscle cells, lymphatic vessel adult stem cells and progenitor cells, neural progenitor cells and nerve cells, insulin secreting cells, and the like by effective 3D culturing using blood mononuclear cells. Therefore, the present invention is expected to be used for development of a cell therapeutic agent for various types of diseases.

Abstract: An apparatus for testing an electronic device may include a field programmable gate array (FPGA), a test board, a test channel and a loop channel. The electronic device may be electrically connected to the test board. The test channel may be electrically connected between the electronic device and the FPGA via the test board. The loop channel may extend from the FPGA, may be connected to the FPGA via the test board, and may be used to test the test board.

Abstract: A pushing force controlling apparatus for a pedal simulator that includes a simulator cylinder in which a first pipe and a second pipe extending from a master cylinder are connected to a front side and a rear side thereof, respectively. A first solenoid valve and a second solenoid valve are installed in the first pipe and the second pipe, respectively and a first piston and a second piston are disposed at a front side and a rear side of an interior of the simulator cylinder. A buffering member is installed between the first piston and the second piston, and pedal pushing force characteristics are controlled by variably setting a position of the second piston in the simulator cylinder using an amount of fluid provided from the master cylinder during an operation of a pedal.

Abstract: A parking lever includes a base plate, a parking lever rotatably mounted to the base plate and having a parking brake cable connected thereto, a ratchet disposed on the base plate, a pawl lever rotatably mounted to the parking lever, a button mounted to the parking lever, a rod operably connecting the button to the pawl lever, and a stopper mounted to the parking lever. The lever is moveable from a released state to a parking state in which the pawl lever is engaged with the ratchet. In one embodiment, the parking lever is not released by operation of only the button to prevent accidental release of the parking brake.

Abstract: Provided are a stereo vision system and a control method thereof. A stereo vision system includes an image information extracting unit receiving left and right images of the left and right stereo cameras to extract color information for a brightness control of the images from the received images, an image preprocessing unit performing a process for reducing noises of the left and right images using the color information and a prestored calibration parameter, a stereo matching unit performing stereo matching of the left and right images processed by the image preprocessing unit through an algorithm to obtain a depth map, and a matching result measuring unit receiving the depth map obtained by the stereo matching unit to measure a matching degree, and changing the prestored calibration parameter according to a result of the measurement.

Abstract: A robotic cellular phone is disclosed. The robotic cellular phone includes a self-environmental recognition function part, a mobility function part, and an emotion function part. The self-environmental recognition function part is for recognizing an external environment by a photo sensor for a sensing luminosity of a surrounding device; a temperature sensor for sensing temperatures of the surrounding device; and a touch sensor for sensing a touch between a human and the surrounding device. The mobility function part is for moving the antenna to an optimum location to increase a sending or receiving signal sensitivity and for opening and closing a folder by using a plurality of wheels formed on a part of rechargeable battery.

Abstract: A driver leg safeguard structure in automobile constructed and arranged to prevent a shin injury of a driver by distancing a pedal from the driver when the pedal is pushed to the driver in the event of a head-on collision or when the driver is pushed to the pedal in the event of sudden stop or collision of automobile, the structure comprising: an upper pedal fixed to an interior at a driver's eat via a rotary axle; a lower pedal rotatably connected to a master cylinder rod via a hinge pin and formed with a pedal part on which the driver steps; and a connecting unit mounted between the upper pedal and the lower pedal for simultaneous rotation of the upper and lower pedals or for rotation of only the lower pedal when the lower pedal is trod.

Abstract: A driver leg safeguard structure in automobile constructed and arranged to prevent a shin injury of a driver by distancing a pedal from the driver when the pedal is pushed to the driver in the event of a head-on collision or when the driver is pushed to the pedal in the event of sudden stop or collision of automobile, the structure comprising: an upper pedal fixed to an interior at a driver's eat via a rotary axle; a lower pedal rotatably connected to a master cylinder rod via a hinge pin and formed with a pedal part on which the driver steps; and a connecting unit mounted between the upper pedal and the lower pedal for simultaneous rotation of the upper and lower pedals or for rotation of only the lower pedal when the lower pedal is trod.